Technical improvements in genetic manipulation of Pichia pastoris and their application in hirudin expression

Research article published in Sheng Wu Gong Cheng Xue Bao (2001)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Research reportFarmacología salivalDesarrollo de fármacosCai CQ et al. · Sheng Wu Gong Cheng Xue Bao, 2001

Abstract

Pichia pastoris has become an increasingly popular host for heterologous protein production. However, there is neither a high-efficient transformation method nor a fast colony-PCR assay for the yeast yet. In this paper, we report a transformation procedure by electroporation, which reaches the value of up to 2800 transformants/microgram DNA. By using a cold and heat treatment and a modified PCR buffer, we established a simple and reliable colony-PCR protocol to detect recombinant P. pastoris clones, which is comparable to the conventional assay for E. coli colonies. With these two novel techniques, we have successfully achieved the expression of hirudin, an antithrombin agent, in Pichia pastoris. The secreted hirudin maintains a biological activity of 82 antithrombian units per milliliter supernatant from the media.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article

Indexed MeSH termsElectroporationHirudinsPichiaPolymerase Chain ReactionTransformation, Genetic

Resumen

Transformation procedure by electroporation reaching 2800 transformants/microgram DNA for Pichia pastoris; expression of hirudin in P.

Por qué esto importa para la hirudoterapia

This article reports improved genetic manipulation techniques for Pichia pastoris — specifically an electroporation transformation method reaching up to 2800 transformants/microgram DNA and a colony-PCR protocol for detecting recombinant clones — and applies them to express hirudin, described as an antithrombin agent. Secreted hirudin showed biological activity of 82 antithrombin units per milliliter of supernatant. The abstract describes hirudin only as an antithrombin agent and makes no mention of leeches, the leech secretome, or hirudotherapy. There is no defensible connection to ASH's domain based on this abstract. This is a methodological study in yeast with no clinical or in-vivo data.

Citación

Technical improvements in genetic manipulation of Pichia pastoris and their application in hirudin expression.

Cai CQ et al. · Sheng Wu Gong Cheng Xue Bao, 2001

DOI PubMed

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Salivary Gland Secretion Anti-Inflammatory Mechanisms Salivary Complex Drug Pipeline Drug Development Direct Thrombin Inhibitors Hirudin Anticoagulation Compounds Otolaryngology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026